Alan Morgan has been appointed to the position of group president of Clinical Research Services at ICON. Mr. Morgan is currently group president of Early Phase and Laboratory Services, and previously was chief operating officer of the ICON Clinical Research division. Mr. Morgan has more than 20 years of experience working in both the pharmaceutical and the CRO industries. Prior to joining ICON, he was vice president and global general manager of the Phase II/IV business of MDS Pharma Services. He also held senior positions in Covance, Glaxo Wellcome and ICI Pharmaceuticals.

Also, Linda Meyerson has joined the company as chief operating officer, ICON Clinical Research. Ms. Meyerson will report directly to Mr. Morgan and brings more than 30 years of pharmaceutical industry experience and drug development knowledge to ICON. Prior to joining the company, Ms. Meyerson was vice president, Global Clinical Operations for GlaxoSmithKline. Previously she served in a similar global capacity for the Janssen Research Foundation and the RW Johnson Pharmaceutical Research Institute.

ICON announced that Dr. John Hubbard, the former group president, Clinical Research Services, is leaving the company to take a senior role at a leading global biopharmaceutical company.

Peter Gray, chief executive officer of ICON, said, “I would like to welcome Alan to his new role. He has been an outstanding member of our management team, and his deep knowledge of our clinical organization and broad industry experience will be invaluable as we continue to develop our business.” Mr. Gray added, “We are also delighted to welcome Linda to our team. Her extensive global drug development experience will be a huge asset to the organization. We are sorry to lose John Hubbard, and I would like to acknowledge his outstanding contribution to ICON and wish him every success in his new challenging role.”